Catalent (CTLT)
(Delayed Data from NYSE)
$56.51 USD
+0.31 (0.55%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $56.58 +0.07 (0.12%) 7:58 PM ET
5-Strong Sell of 5 5
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
CTLT 56.51 +0.31(0.55%)
Will CTLT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CTLT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CTLT
Why Is Catalent (CTLT) Up 0.4% Since Last Earnings Report?
Catalent's (CTLT) Latest Partnership to Boost Clinical Trials
CTLT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up
Catalent (CTLT) Reports Q3 Loss, Misses Revenue Estimates
Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?
Other News for CTLT
Barclays Reaffirms Their Hold Rating on Catalent (CTLT)
Catalent price target raised by $16 at Barclays, here's why
Sarepta cut to Neutral at Citi on risks to valuation
TimesSquare Capital Global Health Care Q1 2024 Commentary
Beyond Elevidys: Unveiling The Competitive Landscape Of Duchenne's Muscular Dystrophy